My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Epratuzumab Biosimilar, CD22 Monoclonal Antibody

Epratuzumab Biosimilar, CD22 Monoclonal Antibody

cluster of differentiation-22, SIGLEC-2, SIGLEC2

Catalog No. Product Name Size List Price (US$) Quantity
C046P Epratuzumab Biosimilar, CD22 Monoclonal Antibody 1 mg 250.00
C046P Epratuzumab Biosimilar, CD22 Monoclonal Antibody 5 mg 750.00
C046P Epratuzumab Biosimilar, CD22 Monoclonal Antibody 20 mg 2000.00
C046P.05 Epratuzumab Biosimilar, Endotoxin 0.05 EU/mg 5 mg 750.00
C046P.05 Epratuzumab Biosimilar, Endotoxin 0.05 EU/mg 20 mg 3000.00
Description

C046P: Epratuzumab Biosimilar, CD22 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human CD22 monoclonal antibody epratuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade epratuzumab biosimilar specifically binds to the human CD22 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by epratuzumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: <1 EU/mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade epratuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab.

Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

Related Links

See our Privacy Policy